Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3961455rdf:typepubmed:Citationlld:pubmed
pubmed-article:3961455lifeskim:mentionsumls-concept:C0033325lld:lifeskim
pubmed-article:3961455lifeskim:mentionsumls-concept:C0311392lld:lifeskim
pubmed-article:3961455lifeskim:mentionsumls-concept:C0205282lld:lifeskim
pubmed-article:3961455lifeskim:mentionsumls-concept:C0442031lld:lifeskim
pubmed-article:3961455pubmed:issue12lld:pubmed
pubmed-article:3961455pubmed:dateCreated1986-4-30lld:pubmed
pubmed-article:3961455pubmed:abstractTextMalignant pericardial effusion (MPE) resulting in cardiac tamponade is a rare complication in neoplastic disease. From January 1975 to December 1984 the authors observed 22 patients with cytologically verified malignant pericardial effusion. The most frequent primary tumors were non-small cell lung cancer (6), breast cancer (5), non-Hodgkin lymphoma (4) and mesothelioma (4). 50% of the patients presented with MPE as the initial manifestation of the tumor. In the other group of patients MPE appeared after an average of 11 months following the diagnosis of malignant disease. The most frequent symptoms and clinical findings were dyspnea (100%), jugular venous distention (91%), and tachycardia (82%). During the first 24 hours after pericardiocentesis a median volume of 675 ml of predominantly serosanguinous effusion was drained. Besides intrapericardial drug instillation, patients also received local radiotherapy and systemic chemotherapy. At the time when MPE was diagnosed 77% of the patients exhibited advanced malignant disease. Mean survival time was 140 days. Malignant pericardial effusion is therefore regarded as an unfavorable prognostic factor.lld:pubmed
pubmed-article:3961455pubmed:languagegerlld:pubmed
pubmed-article:3961455pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3961455pubmed:citationSubsetIMlld:pubmed
pubmed-article:3961455pubmed:statusMEDLINElld:pubmed
pubmed-article:3961455pubmed:monthMarlld:pubmed
pubmed-article:3961455pubmed:issn0036-7672lld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:ReutterF WFWlld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:SennH JHJlld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:RyserD HDHlld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:GloorFFlld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:AngehrnWWlld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:SpielerPPlld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:HoldenerE EEElld:pubmed
pubmed-article:3961455pubmed:authorpubmed-author:SchaermeliKKlld:pubmed
pubmed-article:3961455pubmed:issnTypePrintlld:pubmed
pubmed-article:3961455pubmed:day22lld:pubmed
pubmed-article:3961455pubmed:volume116lld:pubmed
pubmed-article:3961455pubmed:ownerNLMlld:pubmed
pubmed-article:3961455pubmed:authorsCompleteYlld:pubmed
pubmed-article:3961455pubmed:pagination366-70lld:pubmed
pubmed-article:3961455pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:meshHeadingpubmed-meshheading:3961455-...lld:pubmed
pubmed-article:3961455pubmed:year1986lld:pubmed
pubmed-article:3961455pubmed:articleTitle[Malignant pericardial effusion--a sign of unfavorable prognosis?].lld:pubmed
pubmed-article:3961455pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3961455pubmed:publicationTypeEnglish Abstractlld:pubmed